Veno-arterial extracorporeal membrane oxygenation versus standard medical management for massive pulmonary embolism.

IF 1.1 4区 医学 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS
Perfusion-Uk Pub Date : 2024-09-01 Epub Date: 2023-06-07 DOI:10.1177/02676591231182247
Catherine E Kelty, Wael Berjaoui, Nabin K Shrestha, Stephen Fitch, Stefan M Jovinge, Renzo Loyaga Rendon
{"title":"Veno-arterial extracorporeal membrane oxygenation versus standard medical management for massive pulmonary embolism.","authors":"Catherine E Kelty, Wael Berjaoui, Nabin K Shrestha, Stephen Fitch, Stefan M Jovinge, Renzo Loyaga Rendon","doi":"10.1177/02676591231182247","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>There is limited research on the use and outcomes of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) treatment for massive pulmonary embolism (PE). This study compared VA-ECMO treatment for massive PE versus patients treated medically.</p><p><strong>Materials and methods: </strong>Patients diagnosed with massive PE at one hospital system were reviewed. VA-ECMO and non-ECMO groups were compared by <i>t</i> test and Chi-square. Mortality risk factors were identified by logistic regression. Survival was assessed by Kaplan Meier and propensity matching of groups.</p><p><strong>Results: </strong>Ninety-two patients were included (22 VA-ECMO and 70 non-ECMO). Age (OR 1.08, 95% CI 1.03-1.13), arterial SBP (OR 0.97, 95% CI 0.94-0.99), albumin (OR 0.3, 95% CI 0.1-0.8), and phosphorus (OR 2.0, 95% CI 1.4-3.17) were independently associated with 30-day mortality. Alkaline phosphate (OR 1.03, 95% CI 1.01-1.05) and SOFA score (OR 1.3, 95% CI 1.06-1.51) were associated with 1-year mortality. Propensity matching showed no difference in 30-day (59% VA-ECMO versus 72% non-ECMO, <i>p</i> = 0.363) or 1-year survival (50% VA-ECMO versus 64% non-ECMO, <i>p</i> = 0.355).</p><p><strong>Conclusions: </strong>Patients treated with VA-ECMO for massive PE and medically treated patients have similar short- and long-term survival. Further research is needed to define clinical recommendations and benefits of intensive therapy such as VA-ECMO in this critically ill population.</p>","PeriodicalId":49707,"journal":{"name":"Perfusion-Uk","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Perfusion-Uk","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/02676591231182247","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/6/7 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: There is limited research on the use and outcomes of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) treatment for massive pulmonary embolism (PE). This study compared VA-ECMO treatment for massive PE versus patients treated medically.

Materials and methods: Patients diagnosed with massive PE at one hospital system were reviewed. VA-ECMO and non-ECMO groups were compared by t test and Chi-square. Mortality risk factors were identified by logistic regression. Survival was assessed by Kaplan Meier and propensity matching of groups.

Results: Ninety-two patients were included (22 VA-ECMO and 70 non-ECMO). Age (OR 1.08, 95% CI 1.03-1.13), arterial SBP (OR 0.97, 95% CI 0.94-0.99), albumin (OR 0.3, 95% CI 0.1-0.8), and phosphorus (OR 2.0, 95% CI 1.4-3.17) were independently associated with 30-day mortality. Alkaline phosphate (OR 1.03, 95% CI 1.01-1.05) and SOFA score (OR 1.3, 95% CI 1.06-1.51) were associated with 1-year mortality. Propensity matching showed no difference in 30-day (59% VA-ECMO versus 72% non-ECMO, p = 0.363) or 1-year survival (50% VA-ECMO versus 64% non-ECMO, p = 0.355).

Conclusions: Patients treated with VA-ECMO for massive PE and medically treated patients have similar short- and long-term survival. Further research is needed to define clinical recommendations and benefits of intensive therapy such as VA-ECMO in this critically ill population.

大面积肺栓塞的静脉-动脉体外膜氧合与标准药物治疗。
目的:关于静脉-动脉体外膜氧合(VA-ECMO)治疗大面积肺栓塞(PE)的使用和结果的研究很有限。本研究比较了大面积肺栓塞 VA-ECMO 治疗与药物治疗:对一家医院系统中确诊为大面积肺栓塞的患者进行了回顾性研究。VA-ECMO组和非ECMO组通过t检验和Chi-square进行比较。通过逻辑回归确定死亡率风险因素。采用卡普兰-梅耶尔法和倾向匹配法评估各组的存活率:共纳入 92 例患者(22 例 VA-ECMO 和 70 例非ECMO)。年龄(OR 1.08,95% CI 1.03-1.13)、动脉SBP(OR 0.97,95% CI 0.94-0.99)、白蛋白(OR 0.3,95% CI 0.1-0.8)和磷(OR 2.0,95% CI 1.4-3.17)与30天死亡率独立相关。碱性磷酸酶(OR 1.03,95% CI 1.01-1.05)和 SOFA 评分(OR 1.3,95% CI 1.06-1.51)与 1 年死亡率相关。倾向匹配显示,30天生存率(59% VA-ECMO对72%非ECMO,P = 0.363)或1年生存率(50% VA-ECMO对64%非ECMO,P = 0.355)没有差异:结论:接受VA-ECMO治疗的大面积PE患者与接受药物治疗的患者的短期和长期存活率相似。结论:接受VA-ECMO治疗的大面积PE患者与接受药物治疗的患者的短期和长期存活率相似。需要进一步研究,以确定临床建议以及在这类重症患者中采用VA-ECMO等强化治疗的益处。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Perfusion-Uk
Perfusion-Uk 医学-外周血管病
CiteScore
3.00
自引率
8.30%
发文量
203
审稿时长
6-12 weeks
期刊介绍: Perfusion is an ISI-ranked, peer-reviewed scholarly journal, which provides current information on all aspects of perfusion, oxygenation and biocompatibility and their use in modern cardiac surgery. The journal is at the forefront of international research and development and presents an appropriately multidisciplinary approach to perfusion science.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信